Breaking News Instant updates and real-time market news.

YUM

Yum! Brands

$86.74

-1.88 (-2.12%)

10:00
10/06/16
10/06
10:00
10/06/16
10:00

Yum! Brands says has $900M to return to shareholders by year-end

Says investing more in Pizza Hut China ads and promotions.

  • 06

    Oct

  • 11

    Oct

YUM Yum! Brands
$86.74

-1.88 (-2.12%)

09/23/16
09/23/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from Sector Perform by RBC analyst Mark Mahaney, who cut his price target to $14 from $17. The research firm's survey of more than 1,100 advertising professionals and their attitudes towards Facebook (FB), Google (GOOG), Twitter and other high-profile names showed that, despite marketing budgets continuing to shift online, interest in the microblog platform appears to be declining. Of note, Twitter shares have surged this morning after CNBC's David Faber reported that Twitter is moving closer to selling itself and has received expressions of interest in a possible sale, although no deal is imminent. 2. Yum! Brands (YUM) downgraded to Outperform from Top Pick by RBC Capital analyst David Palmer based on valuation. His price target on Yum shares remains $97. 3. Becton Dickinson (BDX) downgraded to Sell from Neutral by Citi analyst Amit Hazan, who thinks a cyclical U.S. slowdown will push the company's organic growth below expectations. The analyst, who also sees a diminishing impact on Becton's growth from emerging markets, cut his price target for the shares to $165 from $167. 4. NextEra Energy (NEE) downgraded to Hold from Buy by Deutsche Bank analyst Jonathan Arnold, as he sees limited near-term upside with the shares up 23% year-to-date. "Extraordinarily frosty commentary" from two of three PUCT commissioners yesterday regarding NextEra's Oncor deal indicates an uphill battle in getting it approved, Arnold tells investors. 5. AVANGRID (AGR) downgraded to Underweight from Neutral by JPMorgan analyst Christopher Turnure, who thinks both the company's growth guidance and consensus expectations "appear ambitious." He lowered his price target for the shares to $41 and $44 and notes he does not have confidence in AVANGRID's near-term growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
OPCO
09/29/16
NO CHANGE
Target $97
OPCO
Outperform
Yum! Brands remains a favorite at Oppenheimer
Oppenheimer analyst Brian Bittner says Yum! Brands remains one of his "favorite Outperforms," despite its 23% year-to-date gain. The analyst raised his price target on the stock to $97 from $96, citing his updated sum-of-parts heading into the October 31 separation of the company's China business. Nonetheless, Bittner notes that this does not incorporate additional potential upside from an attractive G&A opportunity, potential for larger than expected capital returns post-separation at both entities, and continued earnings power restoration at Yum China. He reiterates an Outperform rating on the shares.
09/29/16
BERN
09/29/16
NO CHANGE
BERN
New Yum! poised to benefit from cost cutting, unit growth, says Bernstein
Bernstein analyst Sara Senatore says that New Yum! - the global franchisor of KFC, Pizza Hut, and Taco Bell which will trade separately from the current company's China assets following an upcoming spin off - should benefit from cost cutting and steady unit growth. New Yum! will be able to cut up to $140M+.of costs, and "steady unit growth" should "provide underlying support" for its revenue, she stated. The analyst keeps a $98 price target and Outperform rating on current, combined Yum!.
10/06/16
OPCO
10/06/16
NO CHANGE
Target $97
OPCO
Outperform
Oppenheimer would be aggressive buyer of Yum! Brands below $90
After Yum! Brands reported an in-line earnings quarter, Oppenheimer analyst Brian Bittner remains attracted to the shares ahead of several catalysts. The analyst would be an aggressive buyer of Yum! Brands below $90 per share. He reiterates an Outperform rating and $97 price target on the stock.

TODAY'S FREE FLY STORIES

CELG

Celgene

$117.63

-1.24 (-1.04%)

22:25
12/04/16
12/04
22:25
12/04/16
22:25
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

AAPL

Apple

$109.90

0.41 (0.37%)

, ALNY

Alnylam

$41.57

-0.01 (-0.02%)

21:48
12/04/16
12/04
21:48
12/04/16
21:48
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$109.90

0.41 (0.37%)

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

UTX

United Technologies

$108.22

0.74 (0.69%)

RXN

Rexnord

$20.27

-0.72 (-3.43%)

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

EVC

Entravision

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

DE

Deere

$101.50

-1.2 (-1.17%)

ARCH

Arch Coal

$79.32

1.6 (2.06%)

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

MRK

Merck

$61.13

0.37 (0.61%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

  • 15

    Jan

  • 08

    Mar

  • 13

    Mar

TRIP

TripAdvisor

$46.46

-0.7 (-1.48%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$85.62

0.15 (0.18%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
Citrix rating change  »

Citrix upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 08

    Dec

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.